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Are Australian clinicians monitoring
medication adherence in hematological
cancer survivors? Two cross-sectional studies
Marita C. Lynagh1*, Tara Clinton-McHarg2, Alix Hall1, Rob Sanson-Fisher1, William Stevenson3, Campbell Tiley1
and Alessandra Bisquera4
Abstract
Background: Hematological cancer survivors are growing in number and increasingly rely on oral therapy. Given
known poor outcomes associated with non-adherence and previous evidence that many patients do not fully
adhere to their treatment regimen, this study aimed to determine the degree to which clinicians monitor
adherence to oral medication in hematological cancer survivors.
Methods: Data was combined from two cross-sectional surveys of a heterogeneous sample of 431 hematological
cancer survivors recruited from three outpatient hematology clinics in three different states (n = 215) and one state
cancer registry (n = 216) in Australia. Participants completed a self-administered survey that included demographic
characteristics and a 7-item measure of medication adherence developed by the researchers specifically for the
purpose of the studies.
Results: Of the 431 participants, 37 % (n = 160) reported currently taking daily cancer-related medication. Of these,
14 % (n = 23) were found to be non-adherent with ‘missing a dose’ being the most commonly reported non-adherent
behaviour. Only 41 % of survivors indicated that their hematologist or cancer clinician had ‘always’ asked about their
cancer-related medication during their last six visits.
Conclusions: Non-adherence to oral therapy remains a problem in hematological cancer survivors, yet clinicians in
Australia do not appear to be regularly monitoring adherence in their patients. Given an increasing dependence on
oral therapy in clinical hematology and medical oncology and the importance of medication adherence to optimising
health outcomes, greater effort should be invested in developing effective interventions to improve support and
adherence monitoring by cancer clinicians and GPs.
Keywords: Medication adherence, Hematological cancer, Oral therapy
Background
Patient non-adherence to medication is a well-recognised
problem in all cancer populations [1], including among
hematological cancer patients [2]. Recent findings from
three different studies on adherence to imatinib oral ther-
apy in Chronic Myeloid Leukaemia (CML) patients con-
firm this phenomenon [3–5]. The proportion of patients
not adhering to medication is estimated to be 25 % using
pharmacy and medical claims data [3], 36 % using
self-report and pill counts [4] and 2 % using MEMS
(microelectronic monitoring devices) [5]. Despite median
non-adherence rates being low, Marin and colleagues
found that 26 % of patients were less than 90 % adherent
and 14 % of patients were less than 80 % adherent [5].
Poor medication adherence among hematological cancer
patients plays a significant role in treatment failure [6] and
survival [7]. For example, patients with lower imatinib ad-
herence rates have poorer responses to therapy (such as
loss of cytogenetic responses) and higher medical costs
[3–5]. Given that: 1) the number of hematological cancer
survivors is growing [8]; 2) complex and lengthy treatment
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regimens [9] are becoming increasingly reliant on oral
therapy; and 3) serious adverse outcomes have been asso-
ciated with poor drug adherence, regular assessment of
medication adherence by health care providers in this
population is critical.
To date, a range of factors involving the patient, their
disease characteristics, clinicians and the health care sys-
tem [10, 11] have been found to impact on medication
adherence. These factors include: treatment side effects
[10, 12]; poor patient-doctor relationship [13]; and medi-
cation costs [13]. Patients who lack knowledge about the
side-effects and benefits of medication [14]: feel less
control over their health care [15]; dislike aspects of
their medication [15]; have a poorer disease prognosis
[16]; and perceive inadequacies in their health care deliv-
ery [16], are also less likely to adhere. Having insight
into these factors may assist clinicians in recognising pa-
tients who may be at greater risk of not adhering to oral
therapy.
While disease progression, complications or lack of re-
sponse to therapy may all be signs of poor adherence,
these may nevertheless be absent in a patient who is not
taking oral medication as prescribed. A key component
to improving medication adherence is follow-up and
support [17]. Patients should be regularly asked, in a
non-judgmental way, about their use of medications by
their clinicians [10, 17]. However, a review of the field
has found no studies to date which have investigated the
degree to which clinicians ask cancer survivors about
their adherence to oral therapy.
Further, although hematological cancer survivors are a
diverse group, the few studies investigating medication
adherence published to date have focussed predomin-
antly on adherence in CML patients only and report
wide variations in adherence rates [3–5]. There remains
a vital need to investigate the problem of medication
non-adherence in more heterogeneous hematological
cancer populations to identify the most common pat-
terns of non-adherence behaviours and better under-
stand clinician practice so that effective strategies can be
employed to improve adherence among survivors.
The purpose of this study was to assess self-reported
medication adherence by hematological cancer survivors
and perceived clinician behaviour in relation to monitoring
of their oral therapy adherence. Specifically, it aimed to:
1. Identify the proportion of hematological cancer
survivors in Australia who report non-adherence to
medication;
2. Describe the frequency with which Australian
cancer survivors report being asked about their
medication adherence by their hematologists or
cancer doctors, and their general practitioners (GPs)
or family doctors;
3. Identify demographic and disease characteristics of
survivors associated with infrequent medication
adherence monitoring by clinicians.
Method
Study design & setting
The study combined data from two independent cross-
sectional surveys of adult hematological cancer survi-
vors. In one study, survivors were recruited from three
outpatient hematology treatment clinics in three differ-
ent Australia states, while the second study recruited
survivors from one state cancer registry in a fourth
Australian state. For both studies, the data presented
here on medication adherence was one component of a
much larger national study on the unmet needs of
haematological cancer survivors.
Sample and procedure
Eligible participants were aged 18 years or older at time
of the studies, could read and understand English, and
had a confirmed diagnosis of hematological cancer. For
registry-recruited participants, diagnosis was within the
last 3 years.
At treatment clinics, a hematologist or nurse first
identified potentially eligible patients who were then
approached by a research assistant and invited to take
part in the study from October 2012 to March 2013.
Consenting patients were asked to complete two pen
and paper questionnaires, one in the clinic while waiting
for their appointment (which included demographic and
disease characteristics) and a second questionnaire one
month later that was posted to their home address (con-
taining the medication adherence questions). One writ-
ten reminder was sent to patients who had not returned
their completed survey within two weeks of consenting to
participate. Three hundred and ninety-five (395) patients
were identified as eligible and approached to participate in
the study, and 353 (89 %) consented to participate.
A rolling recruitment method was utilised at the can-
cer registry. Eligible survivors were identified and
approached on an on-going basis between September
2012 and September 2013. Active clinician consent was
employed as the standard patient recruitment procedure
by this registry. This meant that consent was first re-
quired from the treating clinician before the registry
contacted their patients. Contacted patients were asked
if they agreed to have their contact details released by
the registry to the researchers. Participants who con-
sented to having their contact details released were sent
a self-administered pen-and-paper questionnaire. Non-
responders were mailed a second copy of the survey
approximately four weeks later. There were 1480
hematological cancer survivors identified as eligible for
the study. Clinicians consented to the registry
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contacting 616 of these, with missing registry data,
clinician non-response and deceased participants being
the main reasons for clinician non-consent. Of the 616
survivors approached by the registry, 316 (51 %) con-
sented to having their contact details forwarded to the
researchers.
Ethics approval was obtained from the University of
Newcastle Human Research Ethics Committee and the
relevant ethics committees associated with each of the
treatment clinics and the cancer registry.
Measures
Participants completed a self-administered questionnaire
that included questions about demographic characteris-
tics (eg. marital status, education level, employment sta-
tus) and cancer history and treatment. For participants
recruited via the cancer registry, some demographic and
disease characteristics (eg. sex, postcode, country of
birth, cancer type) were obtained directly from the can-
cer registry’s records.
Participants also completed seven items assessing
medication adherence and perceived clinician behaviour
that were developed by the research team in close con-
sultation with hematologists and oncologists. Relevant
medication adherence behaviours were first identified
from a review of the literature, checked against behaviours
reported as important by clinicians, and then arranged
into a draft questionnaire. The draft questionnaire was
sent to three hematologists in Australia and three inter-
national experts in the field of medication adherence for
review. Any possible missing medication adherence behav-
iours identified by the experts were then added to the
questionnaire. Item wording and response options were
also refined. A copy of the final seven items used can be
seen in Table 1.
Statistical analysis
For the purpose of this study, ‘non-adherence’ was de-
fined as reporting at least one of the four behaviour pat-
terns associated with non-adherent behaviour (items 2
to 5 in Table 1). Statistical analysis was undertaken using
SAS version 9.4 (SAS Institute Inc, Cary, NC). For each
of the seven items assessing adherence and clinician be-
haviours, the frequency and percentage of responses were
calculated to identify the proportion of hematological can-
cer survivors who reported non-adherence to medication,
and the frequency with which cancer survivors report be-
ing asked about their medication adherence by their he-
matologists or their general practitioners (GP)/family
doctors. Fisher’s exact analyses were used to compare
medication adherence behaviour by sex, age, rural versus
urban geographical location and cancer type. Rural versus
urban location was defined using postcode at diagnosis,
based on the Australian Bureau of Statistics (ABS) five
categories of the Accessibility and Remoteness Index of
Australia (ARIA+) classification [18]. Participants whose
postcodes fell within the ABS categories of major cities of
Australia and inner regional were classified as ‘urban’.
Those with postcodes falling within the categories of outer
regional, remote and very remote Australia were defined
as ‘rural’. Fisher’s exact test was also used to identify
demographic and disease characteristics associated with
infrequent medication adherence monitoring by clinicians.
While sample size estimates were not calculated for the
sub-studies presented, both of the larger studies from
which they derived were estimated to permit statistical
analyses with a power of 80 % and a significance level of
5 % in relation to the main outcome measures.
Results
Participants
Two hundred and fifteen patients attending outpatient
hematological treatment centres and 216 hematological
cancer survivors recruited through the cancer registry
completed survey items pertaining to medication adher-
ence (total n = 431), representing participation rates of
Table 1 Seven items assessing Medication Adherence &
Clinician Behaviour
Thinking about the prescribed medications you are taking related
to your cancer or treatment side-effects:
1. How many different prescribed medications related
to your cancer or treatment side-effects are you
currently taking EACH DAY?
Nil / 1–2 / 3–4 /
5–6 / 7–8 / 9
or more
2. In the last 7 days, have you missed a dose of
one or more of your medications?
No Yes
3. In the last 7 days, have you taken a medication
at the wrong time? (eg. taken the medication
at lunchtime instead of with breakfast)
No Yes
4. In the last 7 days, have you taken a higher
dose of a medication than as prescribed?
No Yes
5. In the last 6 months, have you stopped taking any
prescribed cancer-related medications without
first getting your doctor’s approval to do so?
No Not sure Yes
6. At your last 6 visits to your hematologist or cancer
doctor, on how many of these occasions did they
ask you whether you have been taking your
cancer-related medications as prescribed?
Always, at every
appointment
Sometimes, but
not at every
appointment
Never
Not sure / can’t
remember
7. At your last 6 visits to your GP or regular doctor,
on how many of these occasions did they ask
you whether you have been taking your
cancer-related medications as prescribed?
Always, at every
appointment
Sometimes,
but not at every
appointment
Never
Not sure / can’t
remember
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54 % and 42 % respectively. Of these, 160 participants
(37 %) reported taking at least one medication each day
related to their cancer diagnosis or treatment side-
effects. The majority of participants were males (55 %)
and only 3 % of participants were aged less than 40 years
(see Table 2). The most common cancer type was mye-
loma (38 %). Participants recruited through treatment
centres differed from those recruited via the cancer
registry in regard to usual residence (p < 0.0001) and
time since diagnosis (p < 0.0001) with treatment centre
participants more likely to live in urban areas and be less
than 2 years post-diagnosis compared with registry-
recruited cancer survivors. Participants differed from
non-participants in regard to age (p = 0.0007) with fewer
participants aged below 50 years and cancer type
(p = 0.029) with higher proportions of participants with
NHL and myeloma and a lower proportion of Hodgkin
lymphoma cancer patients. The study samples did not
differ from non-participants by sex or usual residence.
The 160 participants who reported taking daily medica-
tion differed from non-medication participants in time
since diagnosis (p < 0.0001) with medicated participants
more likely to be diagnosed less than 2 years prior, and
by cancer type (p < 0.0001) with higher proportions of
participants with acute leukaemia and myeloma report-
ing taking cancer-related medications every day.
Medication non-adherence behaviour of hematological
cancer survivors
Of the 160 participants taking daily medications, almost a
quarter (24 %, n = 38) were taking five or more medica-
tions each day (see Fig. 1). Eighty-six percent of partici-
pants prescribed oral therapy were found to be adherent,
with 14 % (n = 23) defined as ‘non-adherent’ according to
the study criteria. The most commonly reported non-
adherent behaviour was missing a dose (9 %, n = 15) with
very few participants failing to take their medication at the
correct time (3 %, n = 4) or ceasing a medication without
Table 2 Demographic and disease characteristics of participantsa
Characteristic Cancer Registry participants
(N = 62)
Treatment Centre participants
(N = 98)
Total (N = 160) Exact p-value
n (%) n (%) n (%)
Sexb Male 26 (49 %) 57 (58 %) 83 (55 %) 0.307
Female 27 (51 %) 41 (42 %) 68 (45 %)
Ageb 18–39 years 1 (2 %) 4 (4 %) 5 (3 %) 0.658
40–49 years 5 (9.4 %) 7 (7 %) 12 (8 %)
50–59 years 18 (34 %) 25 (26 %) 43 (28 %)
60–69 years 12 (23 %) 31 (32 %) 43 (28 %)
70 years and over 17 (32 %) 31 (32 %) 48 (32 %)
Cancer typeb Non-Hodgkin Lymphoma (NHL) 20 (38 %) 18 (18 %) 38 (25 %) 0.051
Acute Leukaemia (AL) 8 (15 %) 11 (11 %) 19 (13 %)
Chronic Lymph Leukaemia (CLL) 3 (6 %) 11 (11 %) 14 (9 %)
Myeloma 19 (36 %) 39 (40 %) 58 (38 %)
Hodgkin Lymphoma (HL) 1 (2 %) 6 (6 %) 7 (5 %)
Other 2 (4 %) 13 (13 %) 15 (10 %)
Usual residenceb Urban 30 (57 %) 95 (97 %) 125 (83 %) <0.0001
Rural 23 (43 %) 3 (3 %) 26 (17 %)
Time since diagnosisb Less than 2 years - 52 (53 %) 52 (34 %) <0.0001
2 years and over 53 (100 %) 46 (47 %) 99 (66 %)
Marital statusb Married/living with partner 51 (84 %) 71 (74 %) 122 (78 %) 0.174
Single, never married 10 (16 %) 25 (26 %) 35 (22 %)
Educationb High school or below 28 (48 %) 45 (50 %) 73 (49 %) 0.818
Trade or TAFE 15 (26 %) 26 (29 %) 41 (28 %)
University degree 15 (26 %) 19 (21 %) 34 (23 %)
Employmentb Currently employed 23 (38 %) 32 (33 %) 55 (35 %) 0.607
Not employed 38 (62 %) 66 (67 %) 104 (65 %)
aParticipants are those who reported currently taking daily cancer-related medications
bTotals may not equal sample size due to missing data values
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their doctor’s approval (3 %, n = 4) (see Table 3). Usual
residence was significantly associated with non-adherence
behaviour with urban participants more likely to be non-
adherent compared with rural (p < 0.007). The only other
factor significantly associated with non-adherence was age
with those aged less than 40 years more likely to report
non-adherence behaviours (p < 0.039).
Monitoring of medication adherence by clinicians
Among hematological cancer survivors on daily oral
therapy, only 41 % indicated that their hematologist or
cancer doctor ‘always’ asked whether they had been tak-
ing their prescribed cancer-related medications during
their last six visits. Almost a quarter (23 %, n = 37) of
participants reported that they were ‘never’ asked about
their medications. A high proportion of participants
(40 %) also indicated that they were never asked whether
they had been taking their prescribed cancer-related
medications by their GP or regular doctor during the
last six visits, with only 29 % reporting being ‘always’
questioned about cancer-related medications by their GP
(see Table 4). There was no significant difference in ad-
herence behavior between participants who reported “al-
ways” being asked by their hematologist or their GP
about medications compared to those who reported that
they were asked only “sometimes” or “never” (p = 0.072).
Factors associated with clinician monitoring of adherence
For both hematologists and regular GPs, no significant
differences were found between cancer survivors who
were ‘always’ asked about taking their cancer-related
medication and those who were not, in relation to the
survivors’ gender, age, cancer type, time since diagnosis,
marital status, education level and number of medica-
tions taken per day (see Table 5).
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Fig. 1 Number of daily prescribed cancer-related medications reported by hematological cancer survivors recruited for each study
Table 3 Medication non-adherence behaviour in hematological cancer survivors
Participants (N = 160)
Medication non-adherence behaviours N %
Missed a dose of 1 or more medications in last 7 days 15 9
Did not take a medication at the correct time prescribed in last 7 days 4 3
Took a higher dose of medication than prescribed in last 7 days 3 2
Stopped taking a prescribed medication without first getting doctor’s approval in last 6 months 4 3
Reported at least 1 or more medication non-adherence behaviour 23a 14
a Some participants reported more than one behaviour
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Discussion
Although many hematological cancers require long-term
management [9], this study found that only 37 % of par-
ticipants were taking daily medication related to their
cancer or side-effects of treatment. As a significant pro-
portion of participants had been diagnosed more than
two years prior to the survey, it is likely that some may
have completed treatment and/or were in the ‘watchful
waiting’ stage of survivorship [19].
Of the 160 survivors who were currently prescribed
oral therapy, the majority (86 %) were found to be ad-
herent. While this provides evidence that medication
non-adherence among hematological cancer survivors
occurs, it suggests that the problem may not be as
Table 4 Clinician assessment of medication adherence in hematological cancer survivors (N = 160)
Clinician behaviour Always N (%) Sometimes N (%) Never N (%) Not sure/can’t
remember N (%)
Hematologist or cancer doctor asked whether you have been taking
cancer-related medications as prescribed during last 6 visitsa
64 (41 %) 48 (30 %) 37 (23 %) 9 (6 %)
GP or regular doctor asked whether you have been taking cancer-related
medications as prescribed during last 6 visitsb
45 (29 %) 42 (27 %) 63 (40 %) 7 (4 %)
aMissing data n = 2
bMissing data n = 3
Table 5 Associations between patient characteristics and clinician monitoring of medication adherence
Monitoring by Hematologist Monitoring by GP or regular doctor
Characteristic Always
(n = 64)
Sometimes or
never (n = 94)
Exact p value Always
(n = 45)
Sometimes or
never (n = 112)
Exact p-value
n (%) n (%) n (%) n (%)
Sexa Male 30 (48 %) 52 (60 %) 0.185 21 (48 %) 61 (59 %) 0.278
Female 32 (52 %) 35 (40 %) 23 (52 %) 43 (41 %)
Agea 18–39 years 2 (3.2 %) 3 (3.4 %) 0.655 2 (4.5 %) 3 (2.9 %) 0.878
40–49 years 7 (11 %) 5 (5.7 %) 4 (9 %) 8 (7.7 %)
50–59 years 19 (31 %) 24 (28 %) 14 (32 %) 28 (27 %)
60–69 years 18 (29 %) 25 (29 %) 12 (27 %) 30 (29 %)
70 years and over 16 (26 %) 30 (34 %) 12 (27 %) 35 (34 %)
Cancer typea Non-Hodgkin Lymphoma 16 (26 %) 21 (24 %) 0.599 14 (32 %) 22 (21 %) 0.253
Acute Leukaemia 7 (11 %) 12 (14 %) 3 (6.8 %) 16 (15 %)
Chronic Lymph Leukaemia 7 911 %) 7 (8 %) 3 (6.8 %) 11 (11 %)
Myeloma 22 (35 %) 35 (40 %) 17 (39 %) 40 (38 %)
Hodgkin Lymphoma 5 (8 %) 2 (2.3 %) 4 (9 %) 3 (2.9 %)
Other 5 (8 %) 10 (11 %) 3 (6.8 %) 12 (12 %)
Usual residencea Urban 52 (84 %) 72 (83 %) 1.000 37 (84 %) 86 (83 %) 1.000
Rural 10 (16 %) 15 (17 %) 7 (16 %) 18 (17 %)
Time since diagnosisa Less than 2 years 24 (39 %) 28 (32 %) 0.486 20 (45 %) 31 (30 %) 0.088
2 years and over 38 (61 %) 59 (68 %) 24 (55 %) 73 % (70 %)
Marital statusa Married/living with partner 17 (27 %) 18 (20 %) 0.336 13 (29 %) 22 (20 %) 0.291
Single, never married 47 (73 %) 73 (80 %) 32 (71 %) 87 (80 %)
Educationa High school or below 27 (45 %) 44 (51 %) 0.309 19 (46 %) 53 (51 %) 0.786
Trade or TAFE 21 (35 %) 20 (23 %) 13 (32 %) 27 (26 %)
University degree 12 (20 %) 22 (26 %) 9 (22 %) 24 (23 %)
Employmenta Currently employed 23 (36 %) 32 (34 %) 0.866 16 (36 %) 38 (34 %) 1.000
Not employed 41 (64 %) 61 (66 %) 29 (64 %) 73 (66 %)
No. of daily medications 2 or less 31 (48 %) 46 (49 %) 1.000 21 (47 %) 56 (50 %) 0.727
3 or more 33 (52 %) 48 (51 %) 24 (53 %) 56 (50 %)
aTotals may not equal sample size due to missing data values
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extensive as previous research has indicated [11]. Our
self-reported non-adherence rate of 14 % is less than the
36 % found by Noens et al. [4] but greater than the 9 %
reported in the findings of the IRIS trial (International
Randomized Study of Interferon versus ST1571) [20].
The difference in reported non-adherence rates could be
due to the fact that previous studies had investigated only
CML patients in contrast to the present study which in-
cluded all major hematological cancers. Further, it is likely
that the 9 % non-adherence rate reported in the IRIS clin-
ical trial [2] was due to the close surveillance and greater
assessment frequency of patients involved in a clinical trial
compared to “real world” patient populations.
The most commonly reported non-adherent behaviour
in the current study was missing a dose, consistent with
broader findings relating to medication adherence for
general health care [21]. However, we were not able to
determine whether this behaviour was unintentional (ie.
simply forgetting) or a deliberate choice to not take a
medication. Previous research has suggested that few
cancer patients intentionally choose to miss a dose [15].
Participants were further not asked to distinguish be-
tween oral cancer medications and medications taken to
prevent or manage treatment side effects, hence it is
possible that when a dose is missed, this could relate to
medications for side-effects.
To our knowledge, this study was the first to examine
clinician behaviour in relation to monitoring medication
adherence in hematological cancer survivors. Only 41 %
of survivors (currently taking oral therapy) reported be-
ing always asked about their medications by their cancer
doctor, with most participants indicating that they were
never or only ‘sometimes’ prompted by either their
hematologist or regular clinician to discuss their cancer-
related medications. Even though survivor self-report
was used as a proxy measure for actual clinician behav-
iour, the perceived low frequency of clinician-initiated
questions regarding medications may be interpreted by
cancer survivors to mean that medications and adher-
ence to a prescribed schedule are not important to their
prognosis. Given evidence that patients’ beliefs about the
costs and benefits of oral therapy is a strong predictor of
adherence [22, 23], further research is needed to investi-
gate the actions of clinicians and their role in guiding
survivors’ beliefs about the risk-benefit ratio. Clinicians
themselves acknowledge the critical role they play in pa-
tient education [4] and endorse the routine assessment
of adherence behaviour in hematological cancer survi-
vors [4, 10]. The perceived poor assessment of medica-
tion adherence by clinicians may reflect an assumption
on the clinician’s behalf that patients are fully adherent
or a belief that survivors with a longer time since diag-
nosis may have already developed a good understanding
of the importance of taking their medication.
Strengths and limitations
This study investigated a diverse sample of hematological
cancer survivors recruited from two different sources as
opposed to focussing on only a single hematological can-
cer type or recruiting patients via treatment centres only.
Many participants had already gone through intensive
treatment and were currently focussed on the long-term
management of their cancer, providing a unique and pre-
viously unexplored hematological cancer population. Des-
pite these strengths, the findings of this study should be
considered within the limitations of the data and study de-
sign. First, adherence was measured using participant self-
report which may over or under-estimate medication
adherence compared to other direct and/or indirect meas-
urement methods [10]. However, in the absence of a gold
standard, patient self-report is still considered to be the
most simple and cost-effective measurement method [10].
Second, as previously noted, clinician monitoring behav-
iour was also measured via patient self-report rather than
direct observation or clinician self-report and as such may
be subject to recall bias. Third, the combined study sam-
ples recruited via two different methods may limit the
generalizability of findings. Given that most participants
were more than two years post-diagnosis and currently
taking few medications, the results obtained may not be
applicable to all hematological cancer patients, particularly
those who are more recently diagnosed. Further, the low
consent rate of participants recruited from the registry
(36 %) may also affect generalisability of results, however
the response rate in the present study is comparable with
other studies utilising cancer registries for recruitment
[24, 25]. Finally, the present study only investigated moni-
toring of adherence by hematologists and regular doctors.
Pharmacists are increasingly playing a critical role in man-
aging medication adherence in patients but were not in-
cluded in the present study [17]. While we attempted to
identify whether there were any specific patient character-
istics associated with clinician monitoring of adherence,
other potential characteristics of clinician behaviour (such
as clinician demographics and health care system factors)
were not measured. Further research should explore these
and other variables to provide a greater understanding of
barriers to medication adherence monitoring by clinicians.
Conclusion
This study has shown that a small but significant pro-
portion of hematological cancer survivors do not adhere
to their oral therapy regimen. Missing a dose of one or
more medications in the last seven days was the most
commonly reported non-adherent behaviour. Despite
the serious consequences associated with non-adherence
to oral therapy and acknowledgement of the need to
provide follow-up support to survivors, the findings pre-
sented here indicate that clinicians are not routinely
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monitoring adherence, or at least survivors are not recal-
ling the occurrence of such monitoring. Future research
should focus on the development of interventions to
support and improve adherence monitoring by cancer
clinicians and GPs.
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